Blunted, more variable insulin action in lipohypertrophy

July 28, 2016

(HealthDay)—Insulin lispro injection into lipohypertrophic tissue (LHT) results in considerable impairment and increased variability in insulin absorption and action, according to a study published in online July 13 in Diabetes Care.

Susanne Famulla, Ph.D., from Profil in Neuss, Germany, and colleagues conducted a crossover study involving 13 patients with type 1 diabetes who received subcutaneous abdominal injections of insulin lispro into LHT and normal adipose tissue (NAT). A euglycemic clamp was performed with two injections each into LHT and NAT on one day; on another day, one injection per region was given before a standardized mixed meal.

The researchers found that LHT reduced absorption and effect compared with NAT, but increased intrasubject variability. Postprandial blood glucose concentrations were increased by 26 percent or more with LHT, and maximum concentrations occurred later. With LHT injections, hypoglycemia occurred numerically less frequently (two versus six patients), while profound hyperglycemia only occurred with LHT injections (two patients). There was no difference for Tmax-INS in either study.

"Insulin absorption and action are blunted and considerably more variable with LHT injection, leading to profound deterioration in postprandial glucose control," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Explore further: Dulaglutide, glargine plus lispro improve glycemic control

More information: Full Text (subscription or payment may be required)

Related Stories

Dulaglutide, glargine plus lispro improve glycemic control

June 20, 2016
(HealthDay)—Dulaglutide and glargine in combination with prandial lispro are associated with a similar percentage of time spent in the normoglycemic range, according to a study published online June 9 in Diabetes, Obesity ...

Insulin LY2605541 tops glargine for glycemic control in T1DM

January 13, 2013
(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 ...

More variability in overnight insulin requirements in T1DM

March 15, 2016
(HealthDay)—For individuals with type 1 diabetes, overnight insulin requirements are significantly more variable than daytime and total daily insulin requirements during closed-loop insulin delivery, according to a study ...

Premixed insulin ups hypoglycemia in inpatients

October 16, 2015
(HealthDay)—For hospitalized patients with diabetes, treatment with premixed insulin results in similar glycemic control but higher frequency of hypoglycemia compared with a basal-bolus regimen, according to a study published ...

Insulin glargine's main metabolic effect as metabolite M1

October 25, 2012
(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration ...

Pramlintide improves glucose control in type 1 diabetes

July 25, 2012
(HealthDay) -- The addition of pramlintide, an analog of the naturally-occurring β-cell peptide amylin, before meals improves blood glucose control in patients with type 1 diabetes receiving insulin through an external ...

Recommended for you

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

Skimping on sleep may contribute to gestational diabetes

October 17, 2017
The amount of time spent sleeping in the United States has dropped significantly in the past twenty years with almost a quarter of women and 16 percent of men experiencing insufficient sleep. Now, a new study has found that ...

Artificial pancreas performs well in clinical trial

October 16, 2017
During more than 60,000 hours of combined use of a novel artificial pancreas system, participants in a 12-week, multi-site clinical trial showed significant improvements in two key measures of well-being in people living ...

Omega-6 fats may help prevent type 2 diabetes

October 11, 2017
The risk of developing type 2 diabetes could be significantly reduced by eating a diet rich in omega-6 polyunsaturated fats, a new study suggests.

Where there's type 1 diabetes, celiac disease may follow

October 10, 2017
(HealthDay)—Parents of young children with type 1 diabetes need to be on the lookout for symptoms of another autoimmune condition—celiac disease, new research suggests.

Type 1 diabetes and the microbiota—MAIT cells as biomarkers and new therapeutic targets

October 10, 2017
Together with colleagues from AP-HP Necker–Enfants Malades Hospital in Paris, scientists from the Cochin Institute (CNRS / INSERM / Paris Descartes University) have discovered that the onset of type 1 diabetes is preceded ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.